Abstract
Rationale
Impulsive-compulsive disorders (ICD) in patients with Parkinson’s disease (PD) have been described as behavioral or substance addictions including hypersexuality, gambling, or compulsive medication use of the dopamine replacement therapy (DRT).
Objectives
A remaining challenge is to understand the neuroadaptations leading to reward bias in PD patients under DRT.
Methods
To this end, the appetitive effect of the D2/D3 agonist pramipexole was assessed after chronic exposure to l-dopa in an alpha-synuclein PD rat model.
Results
Association of progressive nigral loss and chronic l-dopa was required to observe a pramipexole-induced place preference. This behavioral outcome was inhibited by metabotropic glutamate receptor 5 (mGluR5) antagonism while transcriptional profiling highlighted regulations potentially related to the context of psychostimulant addiction.
Conclusion
This study provides evidences strongly suggesting that PD-like lesion and l-dopa therapy were concomitant factors involved in striatal remodeling underlying the pramipexole-induced place preference. Molecular and pharmacological data suggest a key involvement of the glutamatergic pathway in this behavioral outcome.
Similar content being viewed by others
References
Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153:31–43
Belin D, Everitt BJ (2008) Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 57:432–441
Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577–588
Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P (2003) Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762–767
Bisagno V, Cadet JL (2014) Stress, sex, and addiction: potential roles of corticotropin-releasing factor, oxytocin, and arginine-vasopressin. Behav Pharmacol 25:445–457
Black KJ, Hershey T, Koller JM, Videen TO, Mintun MA, Price JL, Perlmutter JS (2002) A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc Natl Acad Sci U S A 99:17113–17118
Bonuccelli U, Del Dotto P, Rascol O (2009) Role of dopamine receptor agonists in the treatment of early Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 4):S44–S53
Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 94:3363–3367
Bordet R, Ridray S, Schwartz JC, Sokoloff P (2000) Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 12:2117–2123
Brown AM, Deutch AY, Colbran RJ (2005) Dopamine depletion alters phosphorylation of striatal proteins in a model of parkinsonism. Eur J Neurosci 22:247–256
Bychkov E, Ahmed MR, Dalby KN, Gurevich EV (2007) Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 102:699–711
Campbell JC, Jeyamohan SB, Cruz PDL, Chen N, Shin D, Pilitsis JG (2014) Place conditioning to apomorphine in rat models of Parkinson’s disease: differences by dose and side-effect expression. Behav Brain Res 275C:114–119
Charbonnier-Beaupel F, Malerbi M, Alcacer C, Tahiri K, Carpentier W, Wang C, During M, Xu D, Worley PF, Girault J-A, et al. (2015) Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia. J Neurosci 35:96–111
Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S, Corsi M, Orzi F, Conquet F (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4:873–874
Cilia R (2012) How neurodegeneration, dopamine and maladaptive behavioral learning interact to produce impulse control disorders in Parkinson’s disease. Basal Ganglia 2:195–199
Collins GT, Cunningham AR, Chen J, Wang S, Newman AH, Woods JH (2011) Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats. Psychopharmacology 219:123–135
Conrad KL, Ford K, Marinelli M, Wolf ME (2010) Dopamine receptor expression and distribution dynamically change in the rat nucleus accumbens after withdrawal from cocaine self-administration. Neuroscience 169:182–194
Decressac M, Mattsson B, Björklund A (2012) Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson’s disease. Exp Neurol 235:306–315
Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210
Engeln M, Ahmed SH, Vouillac C, Tison F, Bezard E, Fernagut P-O (2013b) Reinforcing properties of pramipexole in normal and parkinsonian rats. Neurobiol Dis 49:79–86
Engeln M, Fasano S, Ahmed SH, Cador M, Baekelandt V, Bezard E, Fernagut P-O (2013a) Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann Neurol 74:140–144
Evans A (2011) Dopamine agonist-induced substance addiction: the next piece of the puzzle. J Clin Neurosci 18:191–192
Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59:852–858
Everitt BJ, Robbins TW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8:1481–1489
Frank MJ, Samanta J, Moustafa AA, Sherman SJ (2007) Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 318:1309–1312
Frank, M.J., Seeberger, L.C., and O’Reilly R, C. (2004). By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 306, 1940–1943.
German DC, Manaye KF (1993) Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J Comp Neurol 331:297–309
Haber SN, Fudge JL, McFarland NR (2000) Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 20:2369–2382
Herzig V, Schmidt WJ (2004) Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine. Neuropharmacology 47:973–984
Hoffman DC, Dickson PR, Beninger RJ (1988) The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences. Prog Neuro-Psychopharmacol Biol Psychiatry 12:315–322
Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56:27–78
Kalivas PW (2009) The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 10:561–572
Katajamäki J, Honkanen A, Piepponen TP, Lindén IB, Zharkovsky A, Ahtee L (1998) Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats. Pharmacol Biochem Behav 60:23–26
Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, Dekundy A, Lundblad M, Cenci MA (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol Dis 17:219–236
Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97–129
Lawrence AD, Evans AH, Lees AJ (2003) Compulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry? Lancet Neurol 2:595–604
Ma YJ, Sun XH, Xu XY, Zhao Y, Pan YJ, Hwang CA, Wu VC (2015) Investigation of reference genes in Vibrio parahaemolyticus for gene expression analysis using quantitative RT-PCR. PLoS One 10:e0144362
Maetzler W, Tian Y, Baur SM, Gauger T, Odoj B, Schmid B, Schulte C, Deuschle C, Heck S, Apel A, et al. (2012) Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS One 7:e48042
Marie-Claire C, Benturquia N, Lundqvist A, Courtin C, Noble F (2008) Characteristics of dual specificity phosphatases mRNA regulation by 3,4-methylenedioxymethamphetamine acute treatment in mice striatum. Brain Res 1239:42–48
McClung CA, Ulery PG, Perrotti LI, Zachariou V, Berton O, Nestler EJ (2004) DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res 132:146–154
Neisewander JL, Fuchs RA, Tran-Nguyen LTL, Weber SM, Coffey GP, Joyce JN (2004) Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 29:1479–1487
Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8:1445–1449
Ouachikh O, Dieb W, Durif F, Hafidi A (2013) Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area. Behav Brain Res 252:24–31
Paillé V, Henry V, Lescaudron L, Brachet P, Damier P (2007) Rat model of Parkinson’s disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord Off J Mov Disord Soc 22:533–539
Paxinos G, and Watson C (1998) The rat brain in stereotaxic coordinates (Academic Press).
Piechota M, Korostynski M, Solecki W, Gieryk A, Slezak M, Bilecki W, Ziolkowska B, Kostrzewa E, Cymerman I, Swiech L (2010) The dissection of transcriptional modules regulated by various drugs of abuse in the mouse striatum. Genome Biol 11:R48
Pizzagalli DA, Evins AE, Schetter EC, Frank MJ, Pajtas PE, Santesso DL, Culhane M (2008) Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacol Berl 196:221–232
Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67:58–63
Renthal W, Carle TL, Maze I, Covington HE 3rd, Truong HT, Alibhai I, Kumar A, Montgomery RL, Olson EN, Nestler EJ (2008) Delta FosB mediates epigenetic desensitization of the c-fos gene after chronic amphetamine exposure. J Neurosci 28:7344–7349
Riddle JL, Rokosik SL, Napier TC (2012) Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson’s disease and controls. Behav Brain Res 233:15–23
Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18:247–291
Robison AJ, Nestler EJ (2011) Transcriptional and epigenetic mechanisms of addiction. Nat Rev Neurosci 12:623–637
Russo SJ, Mazei-Robison MS, Ables JL, Nestler EJ (2009) Neurotrophic factors and structural plasticity in addiction. Neuropharmacology 56(Suppl 1):73–82
Sadri-Vakili G, Kumaresan V, Schmidt HD, Famous KR, Chawla P, Vassoler FM, Overland RP, Xia E, Bass CE, Terwilliger EF, et al. (2010) Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine. J Neurosci 30:11735–11744
Sgambato-Faure V, Cenci MA (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson’s disease. Prog Neurobiol 96:69–86
Sgambato-Faure V, Buggia V, Gilbert F, Lévesque D, Benabid A-L, Berger F (2005) Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 64:936–947
Silver N, Best S, Jiang J, Thein SL (2006) Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol 7:33
Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25–43
Staley JK, Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100–6106
Stordeur P, Zhou L, Goldman M (2002) Analysis of spontaneous mRNA cytokine production in peripheral blood. J Immunol Methods 261:195–197
Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, et al. (2010) Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain 133:1111–1127
Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen SG (2012) Primer3—new capabilities and interfaces. Nucleic Acids Res 40:e115
van der Kooy D, Swerdlow NR, Koob GF (1983) Paradoxical reinforcing properties of apomorphine: effects of nucleus accumbens and area postrema lesions. Brain Res 259:111–118
Voon V, Fernagut P-O, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E (2009) Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol 8:1140–1149
Voon V, Pessiglione M, Brezing C, Gallea C, Fernandez HH, Dolan RJ, Hallett M (2010) Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 65:135–142
Weintraub D, Nirenberg MJ (2013) Impulse control and related disorders in Parkinson’s disease. Neurodegener Dis 11:63–71
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589
Wise RA (2009) Roles for nigrostriatal—not just mesocorticolimbic—dopamine in reward and addiction. Trends Neurosci 32:517–524
Zengin-Toktas Y, Authier N, Denizot H, Chassain C, Hafidi A, Llorca PM, Durif F (2013) Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and l-dopa, in bilateral 6-OHDA-lesioned rat. Neuropharmacology 70:74–82
Acknowledgments
This work was funded by grants from the Fondation de France and the Fédération Française des Groupements de Parkinsoniens. Authors thank The Michael J. Fox Foundation for providing the AAV vectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All experiments were approved by the Animal Ethics Committee of the University of Auvergne (CEMEA Auvergne) and the ethics committee for animal use in experimental research of the French Research Ministry (authorization number B6311315).
Conflict of interest
The authors declare that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Loiodice, S., Winlow, P., Dremier, S. et al. Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications. Psychopharmacology 234, 15–27 (2017). https://doi.org/10.1007/s00213-016-4430-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-016-4430-7